Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1

Conditions

Hodgkin Disease 65Lymphoma 39Urinary Bladder Neoplasms 16Carcinoma, Non-Small-Cell Lung 10Melanoma 9Lung Neoplasms 9Urethral Neoplasms 4Recurrence 4Prostatic Neoplasms 4Lymphoma, Large-Cell, Anaplastic 4Testicular Neoplasms 3Neoplasms 3Leukemia 3Glioma 3Central Nervous System Neoplasms 3Astrocytoma 3Testicular Germ Cell Tumor 2Teratoma 2Skin Neoplasms 2Oligodendroglioma 2Neurofibromatosis 1 2Kidney Neoplasms 2HIV Infections 2Carcinoma, Renal Cell 2Breast Neoplasms 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Urothelial Carcinoma of the Bladder 1Ureteral Neoplasms 1Survival Without Progression 1

Interventions

durvalumab 1Vinblastine 1Methotrexate 1Gemcitabine 1Doxorubicin 1Cystectomy 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Bladder Adenocarcinoma × Vinblastine × Clear all
NCT03912818 2023-09-11

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Stanford University

Phase 2 Terminated
7 enrolled 9 charts
GenitourinarySarcoma

Bladder Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡